MD
MDAI.US Spectral AI Inc.
- Market cap
- USD 42.2M
- P/E
- -
- P/B
- 26.08x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MDAI.US undervalued?
Graham numberThe Graham number of Spectral AI Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Spectral AI Inc. fundamental analysis
No fundamental analysis for Spectral AI Inc. yet.
Spectral AI Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Spectral AI Inc.
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation and delivers a binary prediction on the wounds capacity to heal by a specified time point in the future to as…
Full company profileSpectral AI Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Spectral AI Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 15.2M | 25.4M | 18.1M | 29.6M | 19.7M | 15.0M |
| Gross Profit | - | 7.05M | 10.8M | 7.88M | 13.3M | 8.93M | 6.28M |
| Operating Income | - | -4.18M | -2.65M | -13.0M | -6.58M | -8.60M | -12.6M |
| EBITDA | - | -4.09M | -2.24M | -20.1M | -11.5M | -5.42M | -13.0M |
| Net Income | - | -3.99M | -2.91M | -20.9M | -15.3M | -7.57M | -15.2M |
| EPS | - | -0.22 | -0.16 | -1.48 | -0.85 | -0.29 | -0.47 |
| Balance Sheet | |||||||
| Total Assets | 165K | 18.5M | 18.7M | 10.7M | 12.1M | 21.4M | 19.4M |
| Total Liabilities | 141K | 4.79M | 6.72M | 12.4M | 19.3M | 27.1M | 31.5M |
| Shareholders' Equity | 24.3K | 13.8M | 12.0M | -1.71M | -7.25M | -5.73M | -12.1M |
| Cash & Short-term Investments | - | 16.1M | 14.2M | 4.79M | 5.16M | 15.4M | 14.0M |
| Total Debt | 40.0K | 583K | 1.20M | 1.29M | 4.69M | 10.1M | 16.3M |
| Cash Flow | |||||||
| Operating Cash Flow | 3.82M | -2.92M | -1.16M | -13.2M | -9.20M | -9.92M | -15.7M |
| Capital Expenditure | 7.00K | 7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 7.46M |
| Free Cash Flow | - | -2.93M | -1.16M | -13.2M | -9.20M | -9.92M | -15.7M |
| Ratios | |||||||
| ROE | - | -29.0% | -24.3% | - | - | - | - |
| ROA | - | -21.5% | -15.6% | -195.0% | -126.6% | -35.4% | -78.1% |
| Net Profit Margin | - | -26.2% | -11.5% | -115.5% | -51.8% | -38.5% | -101.0% |
| Debt to Equity | 1.64x | 0.04x | 0.10x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Spectral AI Inc. dividends
Spectral AI Inc. has not paid dividends in the last 6 fiscal years.
Who owns Spectral AI Inc.
- Insiders 13.85%
- Institutions 17.42%
- Public & others 68.74%
- Shares outstanding 32.2M
- Free float 27.9M
Top funds holding MDAI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 733K | 2.28% | 0.00% | Sep 2026 |
| Bridgeway Ultra-Small Company | 287K | 0.89% | +44.22% | Jun 2026 |
| Fidelity Extended Market Index | 122K | 0.38% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 83.5K | 0.26% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 30.3K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 28.7K | 0.09% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 18.8K | 0.06% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 6.20K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding MDAI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 994K | 3.09% | +36.92% | Jun 2026 |
| Highlander Partners, L.P. | 900K | 2.80% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 827K | 2.57% | 0.00% | Jun 2026 |
| Bridgeway Capital Management, LLC | 287K | 0.89% | +44.22% | Jun 2026 |
| Jane Street Group LLC | 226K | 0.70% | +2.41% | Jun 2026 |
| UBS Group AG | 226K | 0.70% | +99.81% | Jun 2026 |
| Geode Capital Management, LLC | 223K | 0.69% | -26.10% | Jun 2026 |
| BlackRock Inc | 162K | 0.50% | +32.33% | Jun 2026 |
| LPL Financial Corp | 161K | 0.50% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 143K | 0.44% | +0.61% | Jun 2026 |
| University Of Texas Investment Mgmt Co | 122K | 0.38% | -42.18% | Jun 2026 |
| Rathbone Brothers PLC | 87.0K | 0.27% | -50.00% | Jun 2026 |
| State Street Corp | 75.6K | 0.23% | 0.00% | Jun 2026 |
| Forum Financial Management, LP | 60.5K | 0.19% | 0.00% | Jun 2026 |
| Northern Trust Corp | 50.5K | 0.16% | +57.48% | Jun 2026 |
| Virtu Financial LLC | 41.0K | 0.13% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 32.9K | 0.10% | +21.56% | Jun 2026 |
| JPMorgan Chase & Co | 20.3K | 0.06% | 0.00% | Jun 2026 |
| N.E.W. Advisory Services LLC | 20.0K | 0.06% | +42.93% | Jun 2026 |
| Royal Bank of Canada | 15.5K | 0.05% | 0.00% | Jun 2026 |
Spectral AI Inc. company profile
- Company name
- Spectral AI Inc.
- Ticker
- MDAI.US
- Exchange
- USA Stocks
- Listed since
- Apr 6, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 65
- Fiscal year end
- December
- Address
- 2515 McKinney Avenue, Dallas, TX, United States, 75201
- Phone
- 972 499 4934
- Website
- spectral-ai.com
About Spectral AI Inc.
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation and delivers a binary prediction on the wounds capacity to heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient's wounds. Its system also develops AI-Burn software and MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images. Spectral AI, Inc. is headquartered in Dallas, Texas.
Spectral AI Inc. management
7- Dr. John Michael DiMaio M.D.Founder & Chairman · born 1956
- Mr. Vincent Stanley Capone Esq.CEO & Corporate Secretary · born 1967
- Mr. Stanley MicekChief Operating Officer · born 1962
- Ms. Allison KumarHead of Regulatory Affairs & Clinical Trials · born 1978
- Mr. Louis PercocoGeneral Manager · born 1960
- Mr. Wensheng FanCo-Founder, Chief Innovation Strategist & Senior Advisor to the CEO · born 1970
- Mr. David McGuireChief Financial Officer · born 1979